Evofem Biosciences Signs License and Supply Agreement with Windtree Therapeutics to Reduce PHEXXI Manufacturing Costs by 55%-60%.

Evofem Biosciences has entered into a License and Supply Agreement with Windtree Therapeutics, making Windtree its sourcing partner for PHEXXI, a hormone-free contraceptive vaginal gel. Under the agreement, Windtree will reduce the cost of manufacturing PHEXXI by 55-60%, with no cost to Evofem for tech transfer to the new manufacturer. Evofem maintains ownership of the asset and continues to commercialize PHEXXI in the US and internationally through strategic partnerships.

Evofem Biosciences (EVFM) has entered into a significant strategic agreement with Windtree Therapeutics (WINT), marking a pivotal moment in the company's quest to lower manufacturing costs and expand the reach of its hormone-free contraceptive vaginal gel, PHEXXI. The License and Supply Agreement (L&S) announced on March 26, 2025, sees Windtree acting as Evofem's sourcing partner for PHEXXI, which is currently manufactured by Evofem.

Under the terms of the agreement, Windtree will leverage its extensive manufacturing contacts to reduce the cost of producing PHEXXI by 55% to 60%. This substantial reduction in costs is expected to significantly decrease Evofem's cost of goods sold (COGS) for PHEXXI. Notably, Evofem will not incur any costs for the tech transfer to the new manufacturer, further underscoring the financial benefits of this partnership.

Saundra Pelletier, CEO of Evofem, emphasized the importance of this agreement in a press release, stating, "Global expansion of PHEXXI has always been a critical mandate for Evofem, but a significant hurdle has been high manufacturing costs which make commercialization cost-prohibitive in many markets outside of the U.S." The expected reduction in manufacturing costs will enable Evofem to take PHEXXI into new, price-sensitive global markets, thus empowering women with access to non-hormonal contraceptives.

Jed Latkin, CEO of Windtree, highlighted the collaboration's focus on maintaining the high quality of PHEXXI while reducing costs. "Using our extensive contacts across the globe, we have engaged with a pharmaceutical manufacturer on the plan to produce PHEXXI at a far lower cost while delivering the same high quality product that women and their healthcare providers rely on for hormone-free contraception," Latkin said.

Evofem will maintain ownership of PHEXXI and continue to commercialize it through its dedicated sales team in the United States and through strategic partnerships internationally. One such partnership is with Pharma 1 Drug Store, an Emirati pharmaceutical company that plans to launch PHEXXI in the UAE following regulatory approval.

This agreement signifies a strategic move for Evofem, positioning it to expand its market reach and potentially increase its market share in the global contraceptive market. The partnership with Windtree not only reduces manufacturing costs but also opens doors to new markets, aligning with Evofem's mission to address unmet needs in women's sexual and reproductive health.